ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

226
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
Refresh
11 Nov 2016 12:05

President Trump and Healthcare (And Pharma) Sector: What's Next?

Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare...

02 Nov 2016 15:10

Winds Across the Pacific: What the US Election Will Bring to Asia

The bitter divisiveness of the campaign, between Democrat Hillary Clinton and her Republican rival Donald Trump, reflects the deep disaffection of...

Logo
160 Views
Share
02 Nov 2016 08:31

Revisiting the Bristol-Myers Squibb (BMY US) Bullish Investment Thesis After the Q3 Earnings Report.

In our first report on Bristol Myers Squibb Co (BMY US), we presented our bullish contrarian thesis and considered the common stock undervalued for...

01 Nov 2016 13:06

Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update

 Acadia Pharmaceuticals Inc (ACAD US), our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related...

27 Oct 2016 13:36

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector:Mid-Week Update (October 27)

SummaryWe discuss our portfolio companies Acadia Pharmaceuticals Inc (ACAD US), Portola Pharmaceuticals Inc (PTLA US), Dynavax Technologies Corp...

x